ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0748

Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis

Andreas Kerschbaumer1, Gabriela Supp2, Farideh Alasti1, Josef Smolen2 and Daniel Aletaha1, 1Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 2Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Joint Structure, longitudinal studies, radiography, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is an important outcome in RA clinical trials, most commonly assessed by conventional radiographs and quantified/reported by the modified total Sharp van der Heijde Score (mTSS). The mTSS is assessing erosive (ERO) changes as well as joint space narrowing (JSN; reflecting cartilage wasting) in the small joints of the hands and feet. While erosions are the hallmarks of RA, loss of cartilage has been reported to be highly relevant for functional limitations in RA. The sequence of occurrence of these events is not completely understood.

Methods: Radiographs of RA patients from a large prospective clinical routine cohort were scored using the mTSS by one experienced reader (G.S.) unaware of the aim of this project. Time-to-JSN and time-to-ERO was estimated using survival analyses utilizing the Kaplan-Meier estimator. In additional analyses, patients were stratified based on JSN and/or ERO damage at baseline. Further, potential predictors (demographics, csDMARD/bDMARD treatment/combination therapy) of time-to-ERO and time-to-JSN were evaluated using Cox-regression techniques. All statistical analyses were conducted using SAS v9.4 (Cary, New York, USA).

Results: We assessed 798 patients longitudinally for radiographic progression. JSN occurred significantly earlier than erosions (p< 0.001, Figure 1). After stratification for baseline damage (Figure 2), these differences remained significant with a shorter time-to-JSN in patients without any baseline ERO or JSN (n=44, p=0.008), patients with JSN but no ERO at baseline (n=200, p< 0.001), and patients with baseline ERO and JSN (n=536, p< 0.001). Only in the small group of patients with isolated erosions (without JSN) at baseline there was no difference in time-to-progression of ERO vs. JSN (n=18, p=0.241). Overall, shorter time to progression of ERO was significantly predicted by positivity for rheumatoid factor or anti-citrullinated peptide antibodies (CCP; p< 0.003), as well as by erosions at baseline (p< 0.001) in Cox regression. In contrast, seropositivity for neither RF nor CCP was associated with shorter time to JSN progression (p=0.226); however, baseline concomitant JSN and ERO damage did show to be a significant predictor (p< 0.001).

Conclusion: We identified a significantly shorter time to progression of JSN compared to ERO in this longitudinal cohort of RA patients. JSN remains an important radiographic outcome, as it is strongly associated with impairment of physical function. This calls for a stronger focus on cartilage damage in RA, and a stronger consideration of JSN in routine evaluation of RA radiographs in clinical practice.

Figure 1: Kaplan-Meier analysis showing time to progression of radiographic progression. Curves represent time to first occurance of joint space narrowing (red) and erosive (blue) progression.

Figure 2: Time to progression of structural damage after stratification for baseline damage. A: Patients with erosions and absence of joint space narrowing; B: Patients with absence of erosions and presence of joint space narrowing; C: patients with presence of erosions and joint space narrowing; D: patients with erosions and absence of joint space narrowing.


Disclosure: A. Kerschbaumer, Bristol-Myers Squibb, Celgene, Eli-Lilly, Merck Sharp and Dohme, Novartis, Pfizer, 8, Gilead, 9; G. Supp, None; F. Alasti, None; J. Smolen, AbbVie, 2, 5, 8, AstraZeneca, 2, 5, 8, Eli Lilly, 2, 5, 8, Celgene, 5, 8, Celltrion, 5, 8, Chugai, 5, 8, Gilead, 5, 8, ILTOO, 5, 8, Janssen, 5, 8, Kabi, 5, 8, Novartis-Sandoz, 5, 8, Pfizer Inc, 5, 8, Samsung, 5, 8, Sanofi, 5, 8; D. Aletaha, UCB, 5, 8, Eli Lilly, 5, 8, Gilead Sciences, Inc., 2, 5, Janssen, 5, Sanofi/Genzyme, 5, 8, AbbVie, 2, 5, 8, Amgen, 5, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, Roche, 2, 5, 8, Merck Sharp & Dohme, 2, 5, 8, Bristol-Myers Squibb, 8, Celgene, 5, 8, Medac, 5, 8, Sandoz, 5, 8.

To cite this abstract in AMA style:

Kerschbaumer A, Supp G, Alasti F, Smolen J, Aletaha D. Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/joint-space-narrowing-precedes-erosive-radiographic-damage-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-space-narrowing-precedes-erosive-radiographic-damage-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology